NCT06065592View on ClinicalTrials.gov

Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms

PHASE1RecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
CancerSolid TumorThromboembolismCardiovascular DiseasesImmune System DiseasesInflammatory DiseasesColon CancerBreast CancerProstate CancerHepatocellular CarcinomaLung CancerChemotherapyImmunotherapy
Interventions
DRUG

Palbociclib

Palbociclib will be administered at a dose of 125 mg oral on a 21/7 cycle.

DRUG

Rivaroxaban

Rivaroxaban will be administered at a dosage of 15 mg intravenously twice a day for 21 days, followed by 20 mg once daily for the subsequent 21 days.

GENETIC

SNP

diagnostics of patients' carriers or not of the risk allele(s)

Trial Locations (2)

961

RECRUITING

Haykel Hospital, Tripoli

RECRUITING

Lebanese University, Tripoli

All Listed Sponsors
collaborator

Haykel Hospital

UNKNOWN

lead

Lebanese University

OTHER

NCT06065592 - Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms | Biotech Hunter | Biotech Hunter